Intron A (interferon alfa-2b): clinical overview and future directions

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Recombinant alpha interferons serve as a model for biological compound development.
• Clinical trials have treated over 5,000 patients, revealing general principles for biologicals.

Purpose of the Study:

• To review general principles emerging from the clinical development of recombinant alpha interferons.
• To discuss phase I objectives and strategies for biologicals, considering immune vs. cytotoxic models.
• To analyze toxicity profiles, antibody production, and efficacy data of alpha interferons.

Main Methods:

• Review of clinical trial data from over 5,000 patients treated with recombinant alpha interferons.
• Analysis of dose-response relationships, schedule dependence, and patient stratification.
• Evaluation of toxicity profiles, including fever, flu-like symptoms, CNS effects, hematologic, and gastrointestinal toxicity.
• Assessment of antibody production and serum-neutralizing activity, with a focus on interferon alfa-2b.

Main Results:

• Dose-response relationships and schedule dependence are suggested for alpha interferons.
• Tumor burden and patient subtypes are critical for evaluating biological compound activity.
• Common toxicities include dose-limiting fever/flu-like symptoms; CNS, hematologic, and GI toxicities are generally manageable.
• Serum-neutralizing activity is occasionally reported but may not correlate with loss of clinical activity, as seen in a large interferon alfa-2b study (2.5% incidence).

Conclusions:

• Recombinant alpha interferons provide a prototype for biological drug development, highlighting critical factors for efficacy and manageable toxicity.
• Further research is needed to determine the significance of neutralizing activity and the full therapeutic role of alpha interferons, alone or in combination therapies.